DATA GRAPHICS | Data Byte
In vivo CAR Ts defy cell and gene therapy slowdown, draw pharma deal spree
Gilead’s acquisition of Interius is the third in vivo CAR T cell deal this year
August 21, 2025 11:16 PM UTC
Even as pharma demand for cell and gene therapies declines, in vivo CAR T cells are proving an exception. Gilead’s acquisition of Interius marks the third pharma takeout of an in vivo CAR T cell play this year and the fourth deal for the modality overall.
On Tuesday, the Kite Pharma unit of Gilead Sciences Inc. (NASDAQ:GILD) announced plans to acquire privately-held Interius Biopharmaceuticals Inc. for $350 million, making it the smallest in vivo CAR T acquisition so far this year...